374 related articles for article (PubMed ID: 27451324)
21. Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
Alvisi S; Lami A; Baldassarre M; Lenzi J; Mancini I; Seracchioli R; Meriggiola MC
J Sex Med; 2022 May; 19(5):761-770. PubMed ID: 35370104
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection.
Castelo-Branco C; Biglia N; Nappi RE; Schwenkhagen A; Palacios S
Maturitas; 2015 Aug; 81(4):462-9. PubMed ID: 26071816
[TBL] [Abstract][Full Text] [Related]
23. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
[TBL] [Abstract][Full Text] [Related]
24. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
25. The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment.
Kingsberg SA; Krychman M; Graham S; Bernick B; Mirkin S
J Sex Med; 2017 Mar; 14(3):413-424. PubMed ID: 28202320
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
28. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
[TBL] [Abstract][Full Text] [Related]
29. The Gynogram: A Multicentric Validation of a New Psychometric Tool to Assess Coital Pain Associated With VVA and Its Impact on Sexual Quality of Life in Menopausal Women.
Nappi RE; Graziottin A; Mollaioli D; Limoncin E; Ciocca G; Sansone A; Meriggiola MC; Becorpi AM; Maffei S; Russo N; Jannini EA;
J Sex Med; 2021 May; 18(5):955-965. PubMed ID: 33896758
[TBL] [Abstract][Full Text] [Related]
30. Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.
Salvatore S; Nappi RE; Parma M; Chionna R; Lagona F; Zerbinati N; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2015 Apr; 18(2):219-25. PubMed ID: 25333211
[TBL] [Abstract][Full Text] [Related]
31. Helping Women Understand Treatment Options for Vulvar and Vaginal Atrophy.
Parks DM; Levine J
Nurs Womens Health; 2015; 19(4):298-312. PubMed ID: 26264795
[TBL] [Abstract][Full Text] [Related]
32. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
33. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
35. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
36. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
37. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.
Perino A; Calligaro A; Forlani F; Tiberio C; Cucinella G; Svelato A; Saitta S; Calagna G
Maturitas; 2015 Mar; 80(3):296-301. PubMed ID: 25596815
[TBL] [Abstract][Full Text] [Related]
38. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
[TBL] [Abstract][Full Text] [Related]
39. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey.
Nappi RE; Palacios S; Bruyniks N; Particco M; Panay N;
Menopause; 2019 May; 26(5):485-491. PubMed ID: 30422932
[TBL] [Abstract][Full Text] [Related]
40. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach.
Ettinger B; Hait H; Reape KZ; Shu H
Menopause; 2008; 15(5):885-9. PubMed ID: 18779677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
